Patients with Crohn’s disease who were biologic naive had similar rates of clinical remission and speed of onset whether they were treated with Remicade or Stelara, according to study results.
“Rapidity of symptom relief has become a means by which biologics are differentiated,” Neeraj Narula, MD, from the division of gastroenterology at McMaster University, and colleagues wrote. “TNF alpha antagonists such as [Remicade (infliximab, Janssen)] are often perceived to be the more rapidly acting than biologics with newer mechanisms of action. However, published comparisons for rapidity of symptom relief are generally lacking in CD.”